Alivus Life Sciences announced strong financial results for the second quarter and half year ended September 30, 2026. Revenue from operations grew 16% year-on-year to INR682 crores in Q2 FY27. The company highlighted healthy execution, driven by new product launches and demand across its portfolio, with notable growth in its non-GPL business. Profitability also saw a significant improvement, with EBITDA margins expanding considerably.
Alivus Life Sciences Announces Strong Q2 FY27 Performance
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has reported a robust performance for the second quarter and half year ended September 30, 2026. The company disclosed its financial results, highlighting significant year-on-year growth in both revenue and profitability.
Key Financial Highlights (Q2 FY27)
In the second quarter of fiscal year 2027, Alivus Life Sciences achieved revenue from operations of INR682 crores, marking a substantial 16% increase compared to the same period in the previous year. This growth was attributed to successful new product launches and sustained demand across its existing product portfolio. The company’s non-GPL business demonstrated particularly strong momentum, growing by 20.8% year-on-year and now contributing 79% of the overall revenues. Performance remained healthy across key markets including Europe, Japan, North America, LATAM, and ROW.
Gross profit for the quarter stood at INR439 crores, up 29.5% year-on-year, with gross margins reaching 64.4%. EBITDA for the quarter was reported at INR285 crores, an increase of 47% year-on-year, resulting in EBITDA margins of 41.8%. Adjusted EBITDA margins, excluding a one-time income, were approximately 39.5%, reflecting improved operating efficiencies. Profit After Tax (PAT) for the quarter was INR197 crores, with PAT margins at 28.9%.
Half-Yearly Performance (H1 FY27)
For the first half of FY27, revenue from operations reached INR1,322 crores, a growth of 11.1% year-on-year. Gross profit for H1 was INR825 crores, up 22.9% year-on-year, with gross margins at 62.3%. EBITDA for the first half stood at INR519 crores, an increase of 38.4% year-on-year, and EBITDA margin was 39.3%. PAT for H1 was INR357 crores, with PAT margins at 27%.
Strategic Initiatives and Outlook
Dr. Yasir Rawjee, MD and CEO, highlighted the healthy execution and significant improvement in profitability. He noted the diversification of the revenue base through recently launched products and expressed confidence in the growth outlook, reiterating the FY27 revenue growth guidance of 10% to 12% and EBITDA margins in the 35% to 36% range.
The company’s expansion plans are progressing, with the Solapur facility expected to become operational in Q3 of FY27 and the R&D center at Taloja also on track. Alivus Life Sciences maintains a robust pipeline with over 630 DMF and CEP filings globally as of September 30, 2026. The high-potent API portfolio continues to advance, with 30 new products in the active grid.
Mr. Tushar Mistry, CFO, detailed the financial performance, emphasizing the strong gross margins and EBITDA growth, driven by a favorable product mix and recent launches. The company continues to be net debt-free, with a strong free cash flow of INR270 crores, resulting in cash and cash equivalents of INR1,012 crores as of September 30, 2026.
Q&A Session Highlights
During the Q&A session, management addressed questions on one-off income, gross margin sustainability, the impact of new launches, pricing environment, input cost inflation, the Solapur facility’s strategic importance, and the commercialization timeline for new products, including high-potent APIs and oncology drugs. Discussions also covered the CDMO business growth, technology platforms like flow chemistry and particle engineering, and the company’s long-term vision for growth.
The company reiterated its focus on executing its growth strategy, scaling its portfolio, and strengthening its presence in key global markets to ensure sustainable future growth.
Source: BSE
